Another retrospective study reviewed 257 patients with stage IIa to IIIc breast cancer receiving hypofractionated RNI, with 80.2% patients having PMRT, 99.6% undergoing chemotherapy, 81.3% having hormonal treatment, and 25.3% having anti-HER2 targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.